대한뉴팜

Daehan Nupharm announced that it has received marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its new gastroesophageal reflux disease (GERD) treatment, “Rapiduo Tab.” As part of its transformation into a research-driven pharmaceutical and biotech company, the firm is focusing on the development of both incremental and innovative new drugs. Rapiduo Tab is one of the company’s key pipeline products and represents a novel combination of rabeprazole (a proton pump inhibitor, PPI) and an antacid.Rabeprazole is chemically unstable in acidic environments and rapidly degrades in gastric acid. To address this, Rapiduo Tab combines rabeprazole with magnesium oxide for the first time, allowing magnesium oxide to neutralize gastric acid and raise intragastric pH, thereby protecting rabeprazole from degradation and enabling rapid absorption. This results in faster acid suppression compared to existing therapies. Rapiduo Tab demonstrated a Tmax of less than one hour after administration, confirming superior acid control versus reference products. It also applies dual-core tablet technology to reduce tablet size and improve patient compliance. Rapiduo Tab 10/350 mg is scheduled for launch in March 2024, while the 20/350 mg high-dose formulation is planned for release in the second half of 2024. Daehan Nupharm continues to expand its incremental drug development efforts across both the gastroenterology and cardiovascular therapeutic areas.

Daehan Nupharm announced that its cumulative sales for the third quarter of 2023 reached KRW 153.6 billion, representing a 3.9% increase year-on-year. Cumulative operating profit came to KRW 18.1 billion, with an operating profit margin of 11.8%. The company is steadily progressing toward its annual sales target of KRW 200 billion and plans to further expand R&D investment to strengthen future growth drivers. Daehan Nupharm intends to focus on incremental drug development for prescription pharmaceuticals, while also enhancing dosing convenience through the development of new formulations for diabetes and obesity treatments. Strong growth in injectable products, one of the company’s core business strengths, continues to drive sales. In particular, wellness injections such as Vitamin C Injection and Luthione Injection are posting sustained growth. Sales of Liporase Injection, which contains hyaluronidase, are expected to exceed KRW 9 billion this year. The company’s health functional food segment is also showing steady growth. Daehan Nupharm plans to launch a differentiated collagen product in December, further diversifying its portfolio.

Daehan Nupharm announced that its sales for the first half of 2023 reached KRW 104.4 billion, an 8.6% increase compared to the same period last year. Operating profit was recorded at KRW 12.9 billion. Income before income taxes came to KRW 14.8 billion, and net income was KRW 10.9 billion, representing a decrease of 25.5% and 27.1%, respectively, year-on-year. However, excluding the KRW 8.9 billion reversal of litigation provisions recorded in the previous year, income before income taxes from continuing operations was KRW 10.9 billion and net income was KRW 8.1 billion, reflecting a 35.2% and 32.2% increase compared to the same period last year. The company expects steady sales growth in the second half of the year, supported by planned new product launches and a strengthened R&D pipeline. In addition, Daehan Nupharm plans to expand investment in infrastructure and R&D to enhance its mid- to long-term competitiveness.

Daehan Nupharm has signed a mutual cooperation agreement with Professor Peter Namsoo Kim, a leading authority in hemp research, to conduct the nation’s first joint research on the production of standardized hemp materials.Professor Kim previously served as a professor at Texas State University and is currently a Distinguished Invited Scientist at the Gyeongbuk Institute for Bioindustry, where he leads the Hemp Research Forum.Through this agreement, Daehan Nupharm will apply Professor Kim’s patented domestic technologies and a U.S. patent-pending PK-16 analytical method to pursue GMP production of standardized hemp materials in Korea. Using the PK-16 method, the company will analyze more than 16 microcomponents from locally cultivated hemp and utilize these results to conduct animal testing in Korea and clinical trials in Thailand.This joint research will be carried out in conjunction with Daehan Nupharm’s GMP production facilities in line with ongoing efforts to legalize hemp domestically. The project is expected to serve as a foundation for Korea’s hemp industry. Through this research, the company aims to develop core technologies that expand the application of medical hemp globally and to establish a successful case of convergence research between science and clinical practice.

Daehan Nupharm is expanding the supply of its antivenom product and varicella (chickenpox) vaccine. In November last year, the company signed an agreement with Boran Pharma to launch Korea’s only treatment for pit viper bites, the antivenom injection. In December, it began sales of the country’s first introduced varicella vaccine, and starting this month, it has begun offering the Japanese encephalitis live vaccine.The Boran Dried Pit Viper Antivenom Injection is the only snake venom antidote available in Korea. Upon injection, it rapidly neutralizes venom toxins through antigen-antibody binding, significantly reducing venom concentration within one hour of administration. Particularly, about 44% of snakebite cases reported in autumn are severe. To address this, Daehan Nupharm supplies antivenom to emergency medical institutions to enable prompt treatment of life-threatening acute intoxication.The Variel Vaccine is Korea’s first varicella vaccine and an attenuated live vaccine based on the Oka strain, which represents the most common genotype of varicella-zoster virus (VZV). As one of the National Immunization Program (NIP) vaccines, it is the only varicella vaccine in Korea that can be administered to adolescents and adults as well as children, with no age restrictions.The CDJEVAX Japanese Encephalitis Live Vaccine, launching this month, is the only live vaccine included in the National Immunization Program. Approved in 1989, it has been administered to over 200 million people worldwide over a ten-year period. It was the first vaccine for children to receive WHO Prequalification (PQ) and has demonstrated safety through studies involving more than one million children, showing minimal adverse reactions. With a two-dose regimen providing over 95% preventive efficacy, it offers greater dosing convenience compared to vaccines requiring five doses.This year, Daehan Nupharm aims to expand distribution of these three products and stabilize their market presence, with a goal of achieving combined sales exceeding KRW 5 billion by 2027. The company also plans to strengthen partnerships and advance joint research and development initiatives to ensure sustainable growth.

Daehan Nupharm recorded first-quarter sales of 51.5 billion KRW in 2023, marking a 13% increase compared with the same period of the previous year. Operating profit rose 10.6% year-on-year to 5.5 billion KRW.Each business division is strengthening its research and development activities and reflecting the results in performance. The company’s Industry–Academia–Research Center, located in the 2nd Pangyo Techno Valley, is focusing on the development of improved drugs and biopharmaceuticals. In addition, Daehan Nupharm has newly established the Future Business Division to create synergy among its human pharmaceuticals, veterinary medicines, and bio businesses.To diversify its distribution channels, the company launched several specialized brands: a general health supplement brand, an exclusive brand for veterinary hospitals, and a healthcare brand for clinics. DiNU is a health supplement line sold through online channels, with its dual-capsule probiotic product Pharaotics contributing significantly to sales growth. The veterinary hospital brand DiAnge was launched to develop and supply products “for veterinarians who protect the pets that are angels to their owners.” The new clinic-exclusive brand Dr. DiNU, launched in January, is expanding its product lineup of health supplements available only through medical institutions.Since late last year, Daehan Nupharm has been expanding its vaccine distribution business. In November, the company began sales of Korea’s only pit viper antivenom, followed by the launch of the nation’s first varicella vaccine in December. Starting this month, the company has also begun distribution of a Japanese encephalitis live vaccine, establishing a new revenue stream through vaccine sales.The company is also focusing on R&D for geriatric diseases and continues to release new respiratory, antibiotic, and cardiovascular drugs, which are contributing to revenue growth. In June, Daehan Nupharm plans to launch Newtomega Soft Capsules, a combination drug containing atorvastatin and omega-3 acid ethyl esters, which is expected to further drive sales growth.

This is a professional guide and checklist for the treatment using psychotropic appetite suppressant drugs. Our relevant products: 1) Pentine Tablet (Phendimetrazine 35mg)2) PTM Tablet (Phentermine Hydrochloride 18.75mg)3) Festin Tablet (Phentermine Hydrochloride 37.5mg) Please refer to the attached file for detailed information.

Unlike the health supplements sold through the existing 'DiNU' online mall, Dr. DiNU products are exclusively available for purchase in medical institutions. Initially, two products were released: 'Dr. DiNU Super Arginine Powder 6000' and 'Dr. DiNU Glutamine Powder 6000'. Another product, 'Dr. DiNU Immune Alpha Capsule', is scheduled for release in February. 'Dr. DiNU Super Arginine Powder 6000' contains a high dose of 6000 mg of arginine, aimed at restoring lost vitality in people fatigued by modern life. It comes in a convenient jelly stick form with a natural grape flavor, noted for its excellent sweetness. It also contains four kinds of vitamins, nine amino acids, and fermented mugwort extract powder to support additional nutritional balance. 'Dr. DiNU Glutamine Powder 6000' was launched to promote balanced health through amino acid nutrition. It contains 6000 mg of glutamine to support gut health and includes peach concentrate for sweetness. Additional nutrients include 1000 mg arginine, vitamin A, zinc, and hydrolyzed milk protein, ensuring all essential nutrients are covered. Daehan Nupharm is a company strong in the obesity and well-being pharmaceutical markets. Leveraging this strength, the company plans to release products in the food market that enhance immunity and help overcome nutritional imbalances that may occur during dieting. The goal is to expand the 'Dr. DiNU' section within hospitals to increase presence and accessibility.

Wonsuk Lee was inaugurated as CEO and President of Daehan Nupharm on January 2. Born in 1977, he joined the company in 2004, progressing through roles in the overseas business team, finance team, and management team, and most recently served as Vice President of the Management Headquarters. At the inauguration ceremony held together with the 2023 kick-off meeting, he was awarded the Long-term Service Award and the Daehan Nupharm Person of the Year Award. In his inaugural speech, he outlined future management policies centered on the keywords “listening,” “action,” and “responsibility.” Daehan Nupharm is a pharmaceutical and veterinary medicine manufacturer and distributor focused on developing biopharmaceuticals and improved new drugs. The company plans to launch a variety of pharmaceuticals and health supplements, including ‘Zero-Be’ tablets that improve dosing convenience and ‘Cambel Double’ tablets, which are twice the dosage of the 'Cambel' herbal formula. The company has also been preparing for pet product development for several years and aims to release eight items this year. It is strengthening R&D for new drug development, having completed the Industry-Academia-Research Center in the Second Pangyo Techno Valley in 2021. The center is designed to improve work efficiency and welfare through the keywords “research and development” and “communication.” In his speech, Lee emphasized creating synergies between the human pharmaceuticals, veterinary medicines, and health supplements divisions by newly establishing a Future Business Division and strengthening pipelines across divisions. He expressed his commitment to building a workplace where employees are proud to belong to Daehan Nupharm and rewarded for their achievements as the company grows into a global pharmaceutical and bio company.